Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2364041 Target Snapshot

DNA · NUCLEIC-ACID · Bacteria

Back to Search Search this target Browse approvals Evidence Card
316Compounds
255Assays
0Approved Drugs
28.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

DNA shows approved-linked disease relevance led by amebiasis. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Use amebiasis as the disease frame, then confirm a stable protein accession before cross-source reuse.

Review focus
Disease frame ready

Use amebiasis as the disease frame, then confirm a stable protein accession before cross-source reuse.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
amebiasis

DNA shows approved-linked disease relevance led by amebiasis. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with amebiasis because it currently carries approved-linked support. Linked drugs include METRONIDAZOLE, SECNIDAZOLE, TINIDAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DNA as ChEMBL target CHEMBL2364041. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DNA
NUCLEIC-ACID · Bacteria
As of 2026-09-13
ChEMBL target ID
CHEMBL2364041
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether DNA still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why amebiasis is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDNA
Target TypeNUCLEIC-ACID
OrganismBacteria
ChEMBL ↗ NCBI Nucleotide ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDNA
UniProt AccessionN/A

DNA

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as DNA.

Review nameDNA
OrganismBacteria
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

DNA shows approved-linked disease relevance led by amebiasis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
amebiasis
3 linked drugs · 3 direct · 3 efficacy
Linked drugMETRONIDAZOLE
Linked drugSECNIDAZOLE
Linked drugTINIDAZOLE
Approved-linked Approved
bacterial disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugMETRONIDAZOLE
Linked drugNITROFURANTOIN
Linked drugTINIDAZOLE
Approved-linked Approved
bacterial vaginosis
3 linked drugs · 3 direct · 3 efficacy
Linked drugMETRONIDAZOLE
Linked drugSECNIDAZOLE
Linked drugTINIDAZOLE
Approved-linked Approved
infection
3 linked drugs · 3 direct · 3 efficacy
Linked drugMETHENAMINE HIPPURATE
Linked drugMETRONIDAZOLE
Linked drugMETRONIDAZOLE HYDROCHLORIDE
Approved-linked Approved
trichomoniasis
3 linked drugs · 3 direct · 3 efficacy
Linked drugMETRONIDAZOLE
Linked drugSECNIDAZOLE
Linked drugTINIDAZOLE
Approved-linked Approved
urinary tract infection
2 linked drugs · 2 direct · 2 efficacy
Linked drugMETHENAMINE HIPPURATE
Linked drugNITROFURANTOIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with amebiasis because it currently carries approved-linked support. Linked drugs include METRONIDAZOLE, SECNIDAZOLE, TINIDAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseamebiasis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5019.0
EC508.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL575707 8.05 IC50 9.0 Preclinical
CHEMBL1254452 7.55 IC50 28.0 Preclinical
CHEMBL5273352 6.52 IC50 300.0 Preclinical
CHEMBL4277177 6.22 IC50 600.0 Preclinical
CHEMBL2220021 6.07 IC50 850.0 Preclinical
CHEMBL5279472 5.99 IC50 1020.0 Preclinical
CHEMBL5173726 5.94 Kd 1140.0 Preclinical
CHEMBL5272873 5.82 IC50 1500.0 Preclinical
CHEMBL2220350 5.78 IC50 1660.0 Preclinical
CHEMBL5289990 5.51 IC50 3100.0 Preclinical
Distribution

pChEMBL Value Distribution

7
5.0
5
5.5
2
6.0
1
6.5
0
7.0
1
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

255
Total Assays
18
Tested Compounds
4
Assay Types
Binding — 240 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
nucleic acid format 240 10 6.3
Functional — 10 assays, 18 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 18 5.0
ADME — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
nucleic acid format 4 0 —
Toxicity — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine